DHL expands into specialty pharma with CRYOPDP acquisition

BONN, Germany - DHL Group, a global logistics leader, has acquired CRYOPDP, a prominent courier in the clinical trials and biopharma logistics sector. This move, announced today, is aimed at bolstering DHL’s specialized logistics services within the life sciences and healthcare industries. Concurrently, DHL has entered a strategic partnership with Cryoport, Inc. (NASDAQ: CYRX) to enhance supply chain services for these sectors on a global scale. According to InvestingPro data, Cryoport’s stock has experienced significant volatility, with shares down over 65% in the past year and currently trading at $6.09.

CRYOPDP’s expertise in white-glove courier services, coupled with its operations in 15 countries and handling over 600,000 shipments annually, will be integrated into DHL’s Pharma Specialized Network. This acquisition is expected to complement DHL’s existing Life Sciences and Healthcare business, which generated over EUR 5 billion in revenue in 2024. For Cryoport, which reported annual revenue of $228.4 million and maintains a healthy current ratio of 5.29, this partnership could provide crucial growth opportunities. InvestingPro analysis reveals 6 additional key insights about Cryoport’s business fundamentals and growth prospects.

Oscar de Bok, CEO of DHL Supply Chain, emphasized the acquisition’s significance in expanding DHL’s capabilities to meet the evolving demands of clinical trials, biopharma, and cell & gene therapies. He noted that the partnership with Cryoport would allow DHL to offer integrated end-to-end solutions and improve service capabilities.

Jerrell Shelton, CEO of Cryoport, expressed enthusiasm about the partnership, highlighting the opportunity for Cryoport to extend its reach into growth markets, particularly in the Asia Pacific and EMEA regions.

The acquisition is aligned with DHL Group’s Strategy 2030, focusing on temperature-controlled networks, specialty courier coverage, and integrated solutions, aiming to position DHL as a leader in the pharma industry. The strategic move is also anticipated to yield cost savings and enhance service levels by leveraging DHL’s air capabilities.

For Cryoport, this partnership with DHL is expected to strengthen its execution of business in EMEA and APAC, focusing on its core services and responding to market demand more effectively.

The deal and partnership are subject to regulatory approvals. This expansion is part of DHL’s commitment to becoming a leader in life science and healthcare logistics by 2030, contributing to the company’s vision of achieving net-zero emissions logistics by 2050. While Cryoport operates with a moderate debt level and maintains strong liquid assets, analysts don’t expect profitability this year, with a forecasted EPS of -$0.54 for 2025. Get comprehensive insights and detailed analysis about Cryoport and 1,400+ other stocks through InvestingPro’s exclusive research reports.

The information in this article is based on a press release statement.

In other recent news, Cryoport Inc. reported its financial results for the fourth quarter of 2024, revealing a larger-than-expected loss per share at -0.42 compared to the forecasted -0.29. However, the company exceeded revenue expectations, achieving $59.53 million against the projected $58.64 million. UBS analyst John Sourbeer upgraded Cryoport’s stock rating to Buy, setting a price target of $10, citing the company’s strong position in the cell and gene therapy sector. Meanwhile, Jefferies analyst Matthew Stanton reduced the price target for Cryoport to $6.50 from $8.00, maintaining a Hold rating, and noted that the company’s revenue guidance for 2025 aligns with current predictions.

Cryoport has also introduced a new cryogenic freezer, the MVE Biological Solutions’ High-Efficiency 800 C, designed to enhance storage capabilities for fertility clinics and laboratories. This product launch is part of Cryoport’s ongoing efforts to meet the evolving needs of the life sciences industry. Additionally, DHL Group announced the acquisition of CRYOPDP and a strategic partnership with Cryoport to enhance their supply chain services in the life sciences sector. This partnership aims to expand DHL’s specialized pharma logistics capabilities and strengthen Cryoport’s reach in global growth markets such as APAC and EMEA. These developments highlight Cryoport’s strategic initiatives and position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.